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Background: Human cancer cells can transfer signaling molecules to neighboring and distant cells predisposing
them to malignant transformation. This process might contribute to tumor progression and invasion through
delivery of oncogenes or inhibitors of tumor suppressor genes, derived from the primary tumor cells, to susceptible
target cells. The oncogenic potential of human cancer serum has been described in immortalized mouse fibroblasts
but has not been shown yet in human cells. The objective of this study was to determine whether metastatic
cancer patient sera have the ability to induce neoplastic transformation in immortalized human embryonic kidney
(HEK293) cells, human embryonic stem cells (hESCs), human mesenchymal stem cells (hMSCs) and human adult
liver fibroblasts (hALFs).
Methods: Early passage HEK293 cells, hESCs, hMSCs and hALFs were exposed to cancer patient serum, or cancer
cells-derived condition medium for 3 weeks. Treated cells were analyzed for cell proliferation and transformation
both in vitro and in vivo.
Results: HEK293 cells exposed to cancer serum increased their proliferative capability and displayed characteristics
of transformed cells, as evaluated by in vitro anchorage-independent growth assay and in vivo tumorigenesis in
immunodeficient mice. The same phenotypes were acquired when these cells were cultured in cancer cell line
conditioned medium suggesting that the putative oncogenic factors present in the serum might derive directly
from the primary tumor. Histopathological analyses revealed that the tumors arising from cancer patient serum and
conditioned medium-treated HEK293 cells were poorly differentiated and displayed a high proliferative index. In
contrast, neither of these phenomena was observed in treated hMSCs and hALFs. Intriguingly enough, hESC-treated
cells maintained their self-renewal and differentiation potentials, as shown by in vitro sphere formation assay and
in vivo development of teratomas in immunodeficient mice.
Conclusion: Our results indicate that cancer patients serum is able to induce oncogenic transformation of HEK293
cells and maintain the self-renewal of hESCs. To our knowledge, this is the first study that demonstrates the
oncogenic transformation potential of cancer patient serum on human cells. In depth characterization of this
process and the molecular pathways involved are needed to confirm its validity and determine its potential use in
cancer therapy.
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Metastasis is the leading cause of cancer-related death
[1]. Traditionally, metastasis is described as a complex
process initiated by the detachment, dissemination via
blood flow and engraftment of malignant cancer cells in
distant sites from the primary tumor [2-5]. However, re-
cent experimental and clinical data suggest that metasta-
ses might occur via transfer of biologically active plasma
circulating oncogenes or inhibitors of tumor suppressor
genes from the primary tumor to susceptible target cells
located in distant organs [6,7].
Under both physiological and pathological conditions,
different cell types release microvesicles into their micro-
environment [8,9]. Microvesicles are also found in body
fluids such as plasma, cerebrospinal fluid and malignant
ascites [10-12]. They carry in their lumen and membranes
constituents of the original cell and because of that they
are important mediators of intercellular communication,
via the horizontal transfer of effector bio-molecules (i.e.
mRNA, micro-RNA, DNA, proteins, cell-surface recep-
tors, and lipids) [13-17]. Several types of human cancer
cells have been shown to shed in their surrounding extra-
cellular space and into body fluids cargo entities, named
oncosomes. They permit lateral transfer of their cargo to
neighboring normal cells that promote the activation of
survival and mitogenic signaling pathways, allowing them
to acquire cancer cell characteristics [7,18]. Pioneering
works about this mode of horizontal transfer of oncogenic
traits to target susceptible cells through body fluids called
it “genometastasis” [6,19]. More recent studies had
brought more evidences to support this idea [7,18,20]
and experimental data suggest a role of circulating cell-
free nucleic acids in the oncogenic transformation of
susceptible cultured murine cells [19,20]. Malignant
transformation of normal human cells is a multi-step
process, requiring the co-expression of cooperating on-
cogenes. Mutation of a single gene is not sufficient to
trigger neoplastic transformation in human cells [21].
To examine the hypothesis that factors present in the
serum of patients with metastatic cancer are able to induce
neoplastic transformation of target cells, we used a panel of
primary and immortalized human cell lines. Among them,
only the immortalized human embryonic kidney cell line
(HEK293) was prone to malignant transformation following
exposure to cancer patient serum. These cells are generated
by culture with Adenovirus 5 DNA that results in the inser-
tion of approximately 4.5 kb into chromosome 19 [22].
When exposed to cancer patient sera, treated cells dis-
played characteristics of transformed cells such us in vitro
anchorage-independent growth, increased proliferation and
in vivo tumorigenesis in immunodeficient mice. When the
HEK293 cells were exposed to healthy patient sera none of
the above effects was seen. Similar findings were observed
when the HEK293 cells were cultured in cancer cell line-derived conditioned medium, strengthening the hypothesis
that the effect of the sera might be secondary to factors
produced only by cancer cells. Our data brings new evi-
dences, reinforcing the possible role of a non-conventional
pathway in cancer progression and metastasis.
Methods
Cell lines and culture conditions
Colo-320 cells (human colorectal cancer cell line, ATCC),
HEK293 cells (human embryonic kidney cell line, ATCC),
hESCs (human embryonic stem cells, Line WA01, WiCell),
and hMSCs (human mesenchymal stem cells, Lonza) were
maintained according to the supplier’s recommendations.
Human adult liver fibroblasts (hALFs) were isolated from
normal liver tissue taken from patients undergoing meta-
static cancer resection and following written informed
consent. The healthy liver tissue was minced into approxi-
mately 1-mm3 pieces. Tissue pieces were incubated at 37°C
for 20 min in digestion buffer (RPMI-1640 containing 0.2%
Collagenase, 0.03% DNase, 0.1% BSA, 30 nM Selenium and
antibiotics), minced and filtered through 70 μm mesh. Re-
covered cells were cultured in RPMI-1640 supplemented
with 10% FBS, 0.1% BSA, 0.054% Niacinamide, 0.0005% In-
sulin, 10 μg/ml Transferrin/Fe, 30 nM Selenium, 10−8 M
Hydrocortisone, 50 μM β-mercaptoethanol, 2 mM L-glu-
tamine, and antibiotics.
Undifferentiated hESCs were maintained for less than
50 passages on BD Matrigel™ (BD Bioscience) with mTeSR
medium (Stemcell Technologies) as per manufacturer's
recommendations. For passages and experiments, hESC
colonies were treated with dispase (Stemcell Technolo-
gies) for 10 mins at 37°C, and removed mechanically. For
treatment with cancer patient and control sera (10% v/v),
hESCs were seeded at approximately 150 small clumps
per well previously coated with growth factor reduced
matrigel (BD-Bioscience) and incubated at 37°C in 5%
CO2 for 2 weeks. The medium was changed every second
day. For sphere formation assays, 2 weeks-treated hESCs
were trypsinized, washed and passed through a 40 μm cell
strainer to obtain single cell suspension. 10,000 to 20,000
single cells/well were re-suspended in Mammocult Cul-
ture Medium (Stemcell Technologies) into a six-well
ultra-low attachment plate (VWR). Medium was changed
once a week. Two weeks later, individual spheres were
counted under an inverted microscope at 40x magnifica-
tion. The percentage of cells capable of forming spheres
was calculated as follows: [(number of spheres formed/
number of cells plated) × 100].
Blood collection and serum preparation from cancer
patients and healthy subjects
Patients that had undergone resection of primary cancer
and were readmitted for treatment of metastatic disease
were recruited for this study in the Department of General
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pital (Montreal, Canada), in accordance to an approved
ethics protocol by the Ethics Committee of our hospital
(SDR-10-057). All patients had received chemotherapy
and were presenting with a recurrence of the disease in
the form of metastases to one or more organs (Additional
file 1: Table S1). Healthy volunteer subjects, from our hos-
pital, were also consented for this study. Healthy donors
were recruited based on three criteria: (i) age (35–45 year
old), (ii) no signs and symptoms or personal history of
cancer and (iii) family history negative for cancer. Blood
samples (20 ml) were collected from a peripheral vein in
two vacutainer tubes (Becton Dickinson) containing a
clot-activation additive and a barrier gel to isolate serum.
Blood was allowed to clot for 60 min at room temperature,
followed by centrifugation at 1500 g for 15 min. Serum
was collected and subjected to a second centrifugation at
2000 g for 10 min to clear it from contaminating cells, ali-
quoted and stored at −80°C until use.
Collection of Colo-320 cells conditioned medium
Colo-320 cells were cultured in RPMI-1640 supple-
mented with 10% FBS and 1X penicillin/streptomycin
(Wisent). Medium was collected when cells reached
~80% confluence, and cleared of any remaining cells and
cell debris by centrifugation at 2000 g for 5 min and fil-
tration using a 0.2 μm filter. Medium was aliquoted and
stored at −80°C until use.
Cell culture in human serum and conditioned medium
To confirm that there was no contamination or carry-over
of cells, aliquots of the culture medium were placed in a
culture plate and incubated at 37°C, 5% CO2 for 1 week.
Cells were cultured in their recommended culture
medium until 30% confluence at which point the different
conditions were added to the cells. For the human serum
experiments the culture media was supplemented with
10%v/v of either cancer patient or control serum, which
had been filtered through 0.2 μm filters. Only half of the
media was replaced with complete media containing 10%
v/v human serum, every second day. When the cells
reached 80% confluence, they were passaged using Tryp-
sin/EDTA (Wisent). On the other hand, cancer cells con-
ditioned media was added immediately to a fresh batch of
cultured cells (100% conditioned media). All cultures were
maintained for 3 weeks before analyses.
Population doubling level (PDL) calculation
Cells were considered at population doubling zero at the
first time they are exposed to cancer cell line condition
medium or patient serum-added culture medium. At
every passage, cell number was determined and popula-
tion doubling was calculated using the following for-
mula; PDL = log(Nh/Ni)/log2, where Nh is the numberof cells harvested at the end of the incubation time and
Ni is the number of cells inoculated at the beginning of
the incubation time. Cumulative PDL was calculated by
adding the previous calculated PDL.
Cell proliferation and viability assessment
Cell proliferation was assessed using Alamar Blue
(Thermo Scientific) and CFSE (Invitrogen) labeling fol-
lowing manufacturer’s instructions. Briefly, the assays
were performed at the end of the culture experiments.
Alamar Blue was added to culture medium (100 μl/ml of
medium) and incubated for 6 h. Fluorescence was moni-
tored at 530–560 nm excitation wavelength and 590 nm
emission wavelength in a 96 well plate using a fluores-
cence multiplate reader (FLUOstar OPTIMA, BMG
LABTECH). For CFSE labeling, cultures were treated
with 1 μM CFSE in pre-warmed PBS for 15 min at 37°C.
Labeling solution was replaced by pre-warmed culture
medium, and cells were cultured for 30 min at 37°C to
allow acetate hydrolysis. Cells were washed, incubated
for different time points and analyzed using a FACScan
flow cytometer (Becton Dickinson).
For the analysis of apoptosis, we used AnnexinV/7-AAD
labeling. Dissociated cells were resuspended in AnnexinV
binding buffer, and stained with FITC-AnnexinV
(PharMingen). Just before cell acquisition, 5 μl of 7-
AAD was added and cells were acquired in a FACScan
flow cytometer (Becton-Dickinson).
Soft agar colony formation (anchorage independent cell
growth) assay
Anchorage-independent cell growth was determined by
analyzing the formation of colonies in soft agar. This
in vitro assay is a hallmark of transformed cells. It deter-
mines the (i) incidence of colony formation, that is the fre-
quency of cells able to grow and form colonies, and (ii)
size distribution of these colonies, that reflects growth
speed of cells in a given colony (i.e. the faster the cells
grow, the bigger the colony they form). For this purpose,
the size of all colonies in a given culture condition was de-
termined using ImageJ Software. The values obtained were
then categorized to compare one culture condition to an-
other. Soft agar assays were conducted in 12-well plates in
semi-solid media. After trypsinization, 5.000 cells were
suspended in 10% FBS-supplemented DMEM medium
containing 0.3% noble agar. This suspension was layered
on top 0.8% agar-containing medium. Colonies (contain-
ing at least 50 cells) were scored and photographed after
3–4 weeks of culture under an inverted microscope (Evos
XL AMG, Fisher Scientific).
In vivo tumor growth
Five-week-old female NOD-SCID mice (Jackson Labora-
tory) were used in compliance with McGill University
Abdouh et al. Journal of Experimental & Clinical Cancer Research 2014, 33:86 Page 4 of 12
http://www.jeccr.com/content/33/1/86Health Centre Animal Compliance Office (Protocol 2012–
7280). Cells growing in log phase were harvested by trypsi-
nization and washed twice with HBSS. Mice were injected
subcutaneously with 2.106 million cells in 200 μl HBSS/
Matrigel. When possible, mice were injected in both flanks
to reduce the number of animals used in compliance with
the “Three Rs” principles of the Animal Care Committee
of our institution. Tumor growth was monitored regularly
in all animals and once palpable masses were detected, the
diameter was recorded with a caliper and volume esti-
mated using the following formula V = a × b2 × (π/6)
(where a =major diameter; b =minor diameter and V =
volume) [20]. Animals were euthanized by cervical dis-
location when the tumor was ≥1 cm in diameter. The
resulting xenotransplants were photographed and proc-
essed as indicated below.Immunohistochemistry labelling procedures and
histological analyses
Mice xenotumors and teratomas were collected, fixed
in 10% buffered formalin, embedded in paraffin, and
stained with H&E according to standard protocols or
processed for immunohistochemistry. Briefly, 5 μm tis-
sue sections were dewaxed in xylene and rehydrated
with distilled water. After antigen unmasking, and
blocking of endogenous peroxidase (3% hydrogen per-
oxide), the slides were incubated with anti-cytokeratin
(CAM 5.2) and anti-vimentin antibodies (Ventana). La-
beling was performed using iView DAB Detection Kit
(Ventana) on the Ventana automated immunostainer.
Sections were counterstained lightly with Hematoxylin
before mounting. Histological analyses were performed
by a certified pathologist.Fluorescence-activated cell sorting (FACS)
For cell membrane epitope analyses, cells were labeled
with PerCP-conjugated anti-SSEA-4 antibodies (Abcam).
For intracellular epitope staining, cells were fixed in 4%
paraformaldehyde for 20 min, permeabilized in 0.5% Tri-
tonX100 for 5 min, and incubated with FITC-conjugated
anti-SOX2 and Rho-conjugated anti-OCT4 antibodies
(Abcam). Cells were acquired in a FACScan flow cyt-
ometer (Becton Dickinson) at a flow rate of 250 cells/sec-
ond. Dead cells and cell debris were excluded from
acquisition by gating with FCS and SSC biparametric plot.Statistical analysis
Statistical differences were analyzed using Student’s t test
for unpaired samples. An ANOVA followed by the
Dunnett test was used for multiple comparisons with
one control group. The criterion for significance (p
value) was set as mentioned in figures.Results
Cancer patient sera increased HEK293 cells proliferation
Previous studies had shown that plasma or serum from
cancer patients increased the proliferation and induced
the transformation of mouse immortalized fibroblast
NIH3T3 cells [19], however they were not able to trans-
form human adipose-derived stem cells, a primary non-
immortalized cell line. To validate these conclusions in
immortalized human cells, we used human embryonic
kidney cell line, HEK293. Cells were treated with cancer
patient sera for 3 weeks, with continual medium refresh-
ment (Table 1 and Additional file 1: Table S1). All experi-
ments were initiated with HEK293 cells at passage 31, to
minimize the risk that accumulating mutations might trig-
ger tumorigenesis [23,24]. We used serum from 4 cancer
patients and performed all experiments in 4 plicates (4
wells). First, we quantified cell proliferation by analyzing
cell metabolic activity (Alamar blue assay), cell division
(CFSE label dilution) and population doubling (Figure 1,
and Additional file 2: Figure S1). Independently of the can-
cer serum used, the metabolic activity was significantly
improved when compared to that of cells cultured in con-
trol human serum (range 14-30% increase; mean +/− SD
21 +/− 6%; n = 4, P = 0.015) (Figure 1B). When cells were
labeled with the cell division tracer (CFSE), those treated
with cancer sera diluted CFSE content more efficiently
than those exposed to control serum, suggesting that they
cycled more rapidly (Figure 1C, and Additional file 2:
Figure S1). Increased cell proliferation in cancer patient
sera-supplemented medium was further confirmed by cu-
mulative population doubling analyses. There was 5 to 6 cy-
cles gain at passage 7 in cancer sera cultures (Figure 1A).
These data suggest that cancer patient sera significantly
enhanced the proliferative of HEK293 cells in vitro.
To investigate whether the serum factor(s) involved in
these effects were derived from cancer cells, we cultured
HEK293 cells in the presence of control medium or
colon cancer cell line Colo-320-conditioned medium.
This treatment mirrored what we observed with cancer
sera. When compared to control medium, Colo-320
cells-conditioned medium significantly increased cell
metabolic activity (Figure 1E), cell division (Figure 1F),
and population doubling (At passage 7, there was 3 to 4 cy-
cles gain in conditioned medium cultures) (Figure 1D).
Taken together, these data suggest that cancer cells-
derived factors present in the serum of patients with
cancer affect HEK293 cell growth.
Cancer patient sera did not affect HEK293 cells viability
We next verified if cancer sera affected cell viability
in vitro. Using the same cell cultures, we analyzed cell
viability using AnnexinV/7-AAD staining (Additional file 3:
Figure S2). The data shows that treatments with cancer
patient sera affected neither the percentage of necrotic cells
Table 1 Characteristics of the cancer sera and types of cell lines cultured
Cells/Conditions Animals with tumora Latency (days) Tumor volume (cm3)
HEK293/Control human serum 0/6 30 –
HEK293/Case18 (PcC/LM) 3/3 30 0.930 +/− 0.130
HEK293 /Case21 (Leiomyosarcoma) 3/3 30 0.610 +/− 0.122
HEK293/Case9 (CRC/LM) 3/3 30 0.241 +/− 0.090
HEK293/Case14 (BC/LM) 3/3 30 1.064 +/− 0.073
HEK293/Control medium 0/3 30 –
HEK293/CM-Colo320 3/3 30 0.288 +/− 0.017
hESC WA01/Control human serum 0/2 185 –
hESC WA01/Case23 (CC/LM) 0/2 185 –
hESC WA01/Control human serum 0/5 210 –
hESC WA01/Case4 (GC/Peritoneal seeding) 0/5 210 –
hESC WA01/Control human serum 0/5 120 –
hESC WA01/Case8 (CC/LM) 0/6 120 –
hESC WA01/Control human serum 0/4 155 –
hESC WA01/Case19 (GC/LM) 0/7 155 –
hESC WA01/Control human serum 0/2 119 –
hESC WA01/Case7 (Neuroendocrine) 0/3 119 –
hESC WA01/Control human serum 0/2 104 –
hESC WA01/Case10 (BC/BM + lM) 0/2 104 –
hESC WA01/Control human serum 0/3 60 –
hESC WA01/Case13 (CRC/LM + BM) 0/3 60 –
hALF/Control human serum 0/2 70 –
hALF/Case16 (CRC/LM) 0/2 70 –
hMSC /Control human serum 0/2 98 –
hMSC /Case20 (CC/LM) 0/2 98 –
hMSC /Case22 (BrC/LM + lM) 0/2 98 –
Target cells were exposed for 3 weeks to cancer patient sera or Colo-320 cell line conditioned medium. Cells were inoculated subcutaneously to immunodepressed mice
and mice were monitored for tumor growth.
athis ratio represent the number of mice that develop subcutaneous tumour over the total number of injected mice per cell culture condition.
BC; Breast cancer, BM; Bone metastasis, CC; Colon cancer, CRC; Colorectal cancer, GC; Gastric cancer, hESC; Human embryonic stem cells, hALF; Human adult liver
fibroblasts, hMSC; Human mesenchymal stem cells, LM; Liver metastasis, lM; Lung metastasis, PcC; Pancreatic cancer.
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of apoptotic cells (AnnexinV positive and 7-AAD negative
cells; 1.8 ± 0.1% vs. 1.1 ± 0.4%) (Additional file 3: Figure S2).
In addition, there was no difference observed in cell viabil-
ity between the culture in control medium and these
treated with Colo-320 cells-conditioned medium (necrotic
cells; 3.7 ± 0.3% vs. 4.0 ± 0.5%, and apoptotic cells; 0.9 ±
0.1% vs. 1.4 ± 0.3%) (Additional file 3: Figure S2).
Cancer patient sera transformed HEK293 cells in vitro
The potential to perform anchorage-independent growth is
a hallmark of transformed cells. To test whether HEK293
cells acquire characteristics of transformed cells in vitro,
we treated them as detailed in the previous sections, and
their ability to form colonies in soft agar substrate was
assayed (Figure 2, and Additional file 4: Figure S3). The in-
cidence of colony formation was greater in cancer patientsera-treated cultures when compared to control human
serum-treated cultures (Figure 2B, and Additional file 4:
Figure S3). Also, colony size distribution analyses showed
that cells cultured in cancer patient sera gave rise to larger
colonies when compared to those generated by cells grown
in control human serum (Figure 2A and C, and Additional
file 4: Figure S3).
We performed the same analyses on cells cultured in the
presence of control medium or Colo-320 cells-conditioned
medium. Essentially, we observed the same phenotype. The
incidence of colony formation was greater in conditioned
medium-treated cultures when compared to control
medium-treated cultures (Figure 2E). Furthermore, col-
ony size distribution analyses showed that cells cultured
in cancer cells-conditioned medium gave rise to larger
colonies when compared to those generated by cells
grown in control medium (Figure 2D and F). All
Figure 1 Cancer patient serum and cancer cell line conditioned medium increased HEK293 cells growth. HEK293 cells were cultured for
3 weeks in control human serum, or cancer patient sera (A-C), and in control medium or Colo320 cell line conditioned medium (CM-Colo) (D-F).
Cells were than analyzed for their growth potential. (A and D) population doublings capability was calculated at every passage. Column graphs
represent cumulative population doublings at the end of the treatment periods. (B and E) metabolic activity following 6 hours incubation with
Alamar Blue and spectrofluorometry analyses. (C and F) proliferation following labeling with CFSE probe and cytometry acquisition. Numbers in
brackets are the mean fluorescence intensity (MFI) of each peak. Data are mean ± SD of 2 control sera vs. 4 cancer patient sera (A-C), and 2
control vs. 3 independent batches of conditioned media (D-F). (See Additional file 2: Figure S1 for supplement information)
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and cancer cell conditioned medium have the ability to
transform HEK293 cells in vitro.
Cancer patient sera-treated HEK293 cells generated tumors
in immunocompromised mice
To determine whether cancer sera promote tumor for-
mation in vivo, NOD/SCID mice were injected subcuta-
neously with HEK293 cells exposed to control or cancer
patient sera. Cells were injected following 3 weeks of
treatment. Mice were followed-up for tumor growth,
and once the size of the mass reached 1 cm in diameter,
they were euthanized (4 to 5 weeks after cell inocula-
tion) (Figure 3A-C, Additional file 5: Figure S4 and
Table 1). All mice injected with cancer sera-treated cells
developed visible tumors as early as 2 weeks following
inoculation (Figure 3B). These tumors vary in size from
0.24 to 1.06 cm3 (Figure 3C). In contrast, none of the
mice injected with control human serum-treated cellsdeveloped tumors during the course of the experiments
(5 weeks latency) (Figure 3A-C and Table 1).
Histopathological analyses of the excised tumors
showed that, they had identical histological appearances,
and the types of tumors grown were not dependent of
the patient’s type of cancer. The histology confirmed that
all tumors were poorly-differentiated carcinomas with a
high mitotic index (over 90%) and small foci of necrosis
(Figure 3D i). Immunohistochemical staining showed
high positivity for low-molecular weight Cytokeratin and
Vimentin (Figure 3D ii and iii). Further attempts to
characterize the tumors immunohistochemically failed to
show any more differentiating features as they all stained
negatively for mucin, CK7, CK20, CK19, CEA, Actin,
PAX8 and CDX2.
When cells treated with cancer cells-conditioned medium
were transplanted, all mice developed tumors 3 weeks fol-
lowing inoculation (Figure 3A-C and Table 1). These tu-
mors displayed identical histological appearance when
Figure 2 Cancer patient serum and cancer cell line conditioned medium increased anchorage-independent growth of HEK293 cells.
HEK293 cells were cultured for 3 weeks in control human serum, or cancer patient sera (A-C), and in control medium or Colo320 cell line
conditioned medium (CM-Colo) (D-F). Cells were then grown in soft agar for 2 weeks. (A and D; Bright field pictures), note the increase of
colonies size in the cells exposed to patient sera and Colo320 cell line conditioned medium compared to their respective controls. (B and E) the
graphs represent the number of colonies counted per field. (C and F; Colony size distribution) the sizes of the colonies were measured using
ImageJ software and the frequency of different colony size was calculated. Note that the biggest colonies are formed in the cells exposed to
patient sera and Colo320 cell line conditioned medium. Data are mean ± SD of 2 control sera vs. 4 cancer patient sera (A-C), and 2 control vs. 3
independent batches of conditioned media (D-F). (See Additional file 4: Figure S3 for supplement information)
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tient sera. In contrast, none of the mice injected with con-
trol medium-treated cells developed a tumor as observed
after euthanasia (Figure 3A-C and Table 1). These data
demonstrate that exposure of an immortalized human cell
line to human cancer sera or cancer cells-conditioned
medium transfer tumorigenic traits in vitro and in vivo as
opposed to exposure to healthy patient serum, which fails
to transform HEK293 cells.
Embryonic stem cells and adult human cell lines are
refractory to the oncogenic potential of cancer patient
sera
HEK293 are immortalized cells [22,24] prone to malignant
transformation following transfer of oncogenes [25-28].
To test whether the same effect would be obtained on
cells with a stable genome, we performed another set of
experiments, using a panel of embryonic and adult human
cell lines (i.e. embryonic stem cells (hESCs), mesenchymalstem cells (hMSCs), and adult liver fibroblast (hALFs).
These cells were treated with control or cancer patient
sera (Table 1). Preliminary analyses showed that exposure
of hALFs to cancer patient serum failed to affect cell pro-
liferation as measured by the population doubling capabil-
ity (cumulative population doubling was 25.61 vs. 25.43 at
passage 9), and cell metabolic activity (Alamar blue assay;
9193 ± 582 vs 8871 ± 625, n = 5 independent well cultures,
P > 0.05) in control serum-treated cells compared to can-
cer patient-treated cells (Additional file 6: Figure S5). Also,
this treatment did not transform them (Table 1). On the
other hand, treatment of hMSCs with cancer patient sera
did not affect their cell proliferation as measured by the
population doubling capability (cumulative population
doubling was 19.43 (control serum) vs. 19.78 (case 20) and
20.56 (case 22) at passage 5), cell metabolic activity
(22523 ± 955 (control serum) vs 22596 ± 448 (case 20) and
24372 ± 1014 (case 22), P > 0.05), and cell division (CFSE
label dilution; signal mean fluorescence intensity at 24 hours
Figure 3 Effect of cancer patient serum and cancer cell line conditioned medium on tumorigenicity of HEK293 cells in vivo. SCID/Beige
mice were injected with HEK293 cells cultured for 3 weeks in control human serum, or cancer patient sera, and in control medium or Colo320
cell line conditioned medium (CM-Colo). (A) 4 to 5 weeks after injection, mice were photographed and euthanized. Representative pictures of
tumors are shown. (B and C) tumor growth was monitored weekly. Once tumors were palpable, their diameters were measured (B) and their
volumes at euthanasia were calculated (C). Values are mean +/− SD, (n = 3–6 mice per group). (D) Formalin-fixed paraffin-embedded xenotrans-
plant samples were processed for H&E staining (i), and immunolabeled with antibodies against (ii) cytokeratin or (iii) vimentin (brown). Scale bars,
50 μm. (See Additional file 5: Figure S4 for supplement information)
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129 (case 22) (Additional file 7: Figure S6). Also, these
treatments failed to transform them into neoplastic cells
(Table 1).
As expected, when we treated hESCs with control hu-
man serum, the cells differentiated and downregulated the
expression of pluripotency markers (Figure 4). Moreover,
when these cultures were transferred to low adherence
conditions, they formed few colonies (spheres), which
were vulnerable to dissociation and finally died after the
second passage (Figure 5A and B). However, exposure of
hESCs to cancer patient sera increased their proliferation
(Figure 5) and the cells maintained the expression of pluri-
potency markers as opposed to hESCs treated with control
serum (Figure 4). When cultured in low attachment plates,
hESCs treated with cancer patient sera formed more and
large colonies that were maintained for up to 14–18 serial
passages (Figure 5A and B). When transplanted into
NOD/SCID mice, they did not form malignant epithelialtumors even after longer latency time (Table 1), however
they formed complete teratomas as confirmed by histology
(Additional file 8: Figure S7). Taken together, these data
suggest that, hESCs cultured in cancer patient sera, al-
though refractory to malignant transformation, maintain
their self-renewal ability and are still capable of forming
teratomas when transplanted in mice.
Discussion
In the present study, we report on the oncogenic poten-
tial of cancer patient sera on immortalized human cells.
HEK293 cells incubated with either sera or media from
cancer cells displayed oncogenic properties, such as in-
creased proliferation, enhanced anchor-independent
growth in soft agar and formation of tumors after sub-
cutaneous injection into NOD/SCID mice. To our
knowledge, this is the first study to demonstrate that
cancer patient serum transfers oncogenic features to a
human cell line. The reported findings support the
Figure 4 Cancer patient serum preserved the expression of
stem cell markers of hESCs. hESCs were cultured for 1 or 3 weeks
as monolayer (A-D) or sphere conditions (E) in control human
serum (CTL) or cancer patient sera (see Additional file 1: Table S1).
Cells were than analyzed by flow cytometry for the expression of
stem cell markers.
Figure 5 Cancer patient serum sustained the proliferation and
colony-forming capability of hESCs but did not turn them into
cancerous cells. (A) hESCs were cultured for 10 days in control
human serum (CTL) or cancer patient sera (see Additional file 1:
Table S1), then transferred to stem cell culture medium for 14
additional days. (B) The percentage of colonospheres formed under
each condition. (C) Proliferation of hESCs cultured as monolayer in
either culture media.
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explain cancer traits exchange between malignant and
non-malignant cells that may have implications in can-
cer progression and metastasis. Based on these results,
the hypothesis that dissemination and migration of can-
cer cells from primary tumors might not be the only
mechanism to explain metastases seems rational and
merits further study. The different stages of carcinogenesis
such as initiation, promotion and progression might not
represent events limited to the cells forming the primary
tumor, but may actually be a process reproducible in sus-
ceptible cells, in target organs, through the incorporation
of key factors released by the primary tumor.
Blood-circulating factors (i.e. cell-free nucleic acids) or
factors carried in circulating microvesicles (such as nu-
cleic acids, micro-RNA, mutated and amplified oncogene
sequences and retrotransposon elements) are shed fromseveral types of human tumours [10,12,29-33]. These
factors permit lateral or horizontal transfer of onco-
genic traits to target susceptible cells by activating sur-
vival and mitogenic signals [18-20,29,34,35]. Pioneering
work termed this mode of oncogenic traits transfer
“genometastasis” [6,36] as opposed to the classical seed
and soil theory of metastasis [2-5]. The proof of principle
of the genometastasis theory has been reported earlier
by different groups using an immortalized mouse fibro-
blast cell line (i.e. NIH3T3, p16INK4a/p19ARF deficient)
[19,20,37,38]. Although the authors showed that human
cancer serum increased cell proliferation, promoted
tumor formation and angiogenesis in the NIH3T3 cells,
no studies so far have been able to replicate the same
results with a human cell line. The reason for this lies in
the recognized concept that more than one oncogene
activation or tumor suppressor mutation is necessary to
trigger neoplastic transformation in human cell lines
[39]. To prove the concept that transfer of genetic ma-
terial from cancer cells, mediated through the blood
stream, might be able to complete malignant transform-
ation in “initiated” human cell, we used an immortalized
human cell line (HEK293) [22,24] as a model. This cell
line was shown to be prone to malignant transformation
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therefore it seemed to fulfill the criteria to represent a
valid representation of an initiated cell. In our study,
cells were used at relatively early passage (between 30
and 37), to minimize the risk that spontaneously occur-
ring mutations might trigger tumorigenesis [23,24].
Our data demonstrate that serum of patients with
metastatic cancer contains tumorigenesis-signaling fac-
tors that, once delivered to recipient target cells, might
complete the cascade of events that eventually leads
them to acquire malignant traits. In contrast, normal
cells (i.e. hMSCs and hALFs) were still refractory to the
transforming potential of cancer patient serum, con-
firming the concept that target cells must be first
primed or initiated to undergo transformation. The
“initiation” prerequisite for target cells to be able to
integrate key genes, shed by the primary tumor, and be-
come susceptible to the effect of the factor(s), circula-
ting in the bloodstream of patients with metastatic
cancer, was also reported in an in vivo model of lateral
transfer of malignant trait [20]. In this study, the au-
thors showed that only rats receiving the initiating car-
cinogen 1,2-Dimethylhydrazine and subcutaneous
inoculation of SW480 colon-cancer cells developed
colon cancer and peritoneal carcinomatosis as opposed
to rats receiving subcutaneous inoculation of SW480
cells only, which failed to develop cancer.
Noteworthy, in our study, we used cancer patient serum
instead of plasma, as reported by other authors [19,40].
Controversy exists about the choice between plasma and
serum during screening for biomarkers of malignancy due
to the fact that serum contains higher amounts of cell-free
DNA when compared to plasma [33]. Despite this differ-
ence, several studies reported similar results after exposing
NIH-3T3 cells to the two conditions [19,20,40]. Therefore,
the choice of either serum or plasma should not have any
impact on the results of the experiments.
The oncogenic effects of cancer cells conditioned
medium, mirrored what we observed with cancer pa-
tient sera, strongly suggesting that the circulating
factors, inducing these effects, are derived from pri-
mary cancer cells and are not present in patients
that are not affected by cancer. Previous studies
brought evidences for the role of circulating cell-free
nucleic acids in the oncogenic transformation of sus-
ceptible cells [19,20]. Further studies need to be per-
formed to clarify the nature of other factors involved
in this process, the mechanism of action and to determine
which cells are targeted in vivo. We are currently investi-
gating our hypothesis that the integration of these key
genes shed by the primary tumors might preferentially tar-
get cells, located in organs deriving from the same em-
bryological layer. This concept would represent an
intriguing explanation for metastases that do not followan anatomical pattern of propagation (i.e. melanoma of
the skin metastasizing to the brain or adrenal gland) and
would be an interesting integration to the seed and soil
theory.
Cell fate transition takes place during physiological,
pathological processes and experimental manipulations
(i.e. embryonic development, tumor progression and
somatic cell reprogramming) [41]. It is characterized by
loss of certain phenotypes and acquisition of others. In
our study, the histology confirmed that all tumors were
poorly-differentiated carcinomas. Interestingly, immu-
nohistochemical staining displayed high positivity for
both epithelial and mesenchymal markers: low molecu-
lar weight Cytokeratin and Vimentin, respectively. It is
worth to note that the anti-Cytokeratin antibody we
used is designed to help in the identification of tumors
of epithelial origin, and in distinguishing carcinomas
from other malignant tumors of non-epithelial origin.
Our results suggest that an epithelial to mesenchymal
transition (EMT) occurred in transformed HEK293
cells. These results mimicked those obtained in HCCR-
1 stably transfected HEK293 cells [25]. A connection
has been made between EMT and cancer stem cells
[42], which points to the possible involvement of such
processes during HEK293 cells transformation.
An interesting finding in our experiments was that
hESCs cultured with sera of patients with metastatic
cancer were able to maintain their stemness and
formed teratomas when transplanted in NOD/SCID
mice. This observation suggests the presence in the
cancer patient sera of factors that preserve two of the
main characteristics of cancer stem cells, which are
self-renewal and ability to differentiate. This discovery
strengthens the hypothesis that some substances might
be circulating in the blood of patients with cancer,
which not only are able to trigger tumorigenesis in an
immortal cell line but also might inhibit differentiation
of stem cells thus favoring their transformation into
cancer stem cells.
Conclusion
Metastasis is a long-term process where metastatic le-
sions develop long after the onset of the primary tumor.
The horizontal malignant trait transfer concept is ham-
pered by the lack of long term in vivo data. Ongoing
studies needs to be conducted to solve this issue. Our
findings strengthen the hypothesis that malignant traits
can be transferred through the blood stream and affect
initiated cells even in humans. The results obtained im-
prove the knowledge acquired so far about a non-
conventional pathway of cell-to-cell communication
and highlight the importance that such communication
might have in the progression and invasion in human
cancer.
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Additional file 1: Table S1. Clinical features of patients recruited in the
present study.
Additional file 2: Figure S1. Cancer patient serum and cancer cell line
conditioned medium increased HEK293 cells growth. HEK293 cells were
cultured for 3 weeks in control human serum, or cancer patient sera
(A), and in control medium or Colo320 cell line conditioned medium
(CM-Colo) (B). Cells were than analyzed for their proliferation following
labeling with CFSE probe and flow cytometry acquisition. Numbers in
brackets are the mean fluorescence intensity (MFI) of each peak.
(Related to Figure1).
Additional file 3: Figure S2. Cancer patient serum and cancer cell line
conditioned medium does not affect HEK293 cells viability. HEK293 cells
were cultured for 3 weeks in control human serum, or cancer patient
sera (A and B), and in control medium or Colo320 cell line conditioned
medium (CM-Colo) (C and D). Treated cells were analyzed for cell viability
using AnnexinV and 7AAD staining, and flow cytometry analyses (A and
C). The percentage of necrotic cells (7AAD positive) and apoptotic
(AnnexinV positive and 7AAD negative) cells were ploted for comparison
(B and D). Column graphs represent pooled data from 2 control vs. 4
cancer patient sera (B), and 2 control vs. 3 independent batches of
conditioned media (D). No significant difference was seen in either
treatments groups (P value is > 0.05).
Additional file 4: Figure S3. Cancer patient serum increased
anchorage-independant growth of HEK293 cells. HEK293 cells were
cultured for 3 weeks in control human serum, or cancer patient sera. Cells
were than grown in soft agar for 2-3 weeks. Note the increase of colonies
size in cancer patient-exposed cells compared to those cultured in CTL.
(Related to Figure 2).
Additional file 5: Figure S4. Effect of Cancer patient serum on
tumorigenicity of HEK293 cells in vivo. SCID/Beige mice were injected
with HEK293 cells cultured for 3 weeks in control human serum (A), or
Colorectal (Case9; right flank) or breast (Case14; left flank) cancer patient
sera (B). After 5 weeks of injection, mice were photographed and
euthanized. Representative pictures of tumors are shown. (Related to
Figure 3). (TIFF 5692 kb).
Additional file 6: Figure S5. Cancer patient serum did not affect liver
fibroblasts growth. Cells were cultured for 3 weeks in control human
serum or Colorectal cancer patient serum (Case16). (A) Cells were
analyzed for their population doublings capability calculated at every
passage. Column graphs represent cumulative population doublings at
the end of the treatment periods. (B) Cells were analyzed for their
metabolic activity following 6 hours incubation with Alamar Blue and
spectrofluorometry analyses.
Additional file 7: Figure S6. Cancer patient serum did not affect
mesenchymal stem cells growth or viabilty. Cells were cultured for 3
weeks in control human serum, Colon (Case20) or breast (Case22) cancer
patient sera. Cells were than analyzed for (A) population doublings
capability calculated at every passage (Column graphs represent
cumulative population doublings at the end of the treatment periods),
(B) metabolic activity following 6 hours incubation with Alamar Blue and
spectrofluorometry analyses, (C) proliferation following labeling with CFSE
probe (The CFSE fluorescence intensity was measured by flow cytometry
just after loading (1), or at 18 hours (2) and 24 hours (3) post-labeling),
and (D) cell viabilty using AnnexinV and 7-AAD staining, and flow cytometry
analyses.
Additional file 8: Figure S7. hESCs treated in vitro with cancer patient
sera formed teratomas when transplanted into NOD/SCID mice.
Histological analysis of teratoma formed after transplantation of cancer
patient serum treated hESCs. The panel shows H&E staining of a section
of a teratoma showing ectodermal, endodermal and mesodermal
structures. (TIFF 5548 kb).
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